302 related articles for article (PubMed ID: 19874269)
1. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
Sigurdsson EM
Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson EM
J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
[TBL] [Abstract][Full Text] [Related]
3. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
5. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
Tripathi T; Khan H
Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
[TBL] [Abstract][Full Text] [Related]
6. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
7. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
Boutajangout A; Wisniewski T
Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
[TBL] [Abstract][Full Text] [Related]
8. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2010 Dec; 30(49):16559-66. PubMed ID: 21147995
[TBL] [Abstract][Full Text] [Related]
10. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
[TBL] [Abstract][Full Text] [Related]
11. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
12. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
13. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
Walls KC; Ager RR; Vasilevko V; Cheng D; Medeiros R; LaFerla FM
Neurosci Lett; 2014 Jul; 575():96-100. PubMed ID: 24887583
[TBL] [Abstract][Full Text] [Related]
14. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
Rosenmann H
Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
17. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
18. Tau immunotherapy and imaging.
Sigurdsson EM
Neurodegener Dis; 2014; 13(2-3):103-6. PubMed ID: 24029727
[TBL] [Abstract][Full Text] [Related]
19. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
20. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
